AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06686407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open lumbar decompression ± fusion
Description: Open lumbar decompression by laminectomy and transpedicular screw fixation using screws and rods ± interbody cage device
Study NCT06686407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive lumbar foraminal decompression using unilateral biportal endoscopy device
Description: A new endoscopic technique that uses a Unilater Biportal Endoscopy for lumbar foraminal decompression
Study NCT06164730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERVE-102
Description: Intravenous (IV) infusion
Study NCT06117241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMAGINE HEALTHY
Description: An anti-inflammatory nutrition program including cooking classes, physical activity, and stress reduction.
Study NCT05156476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve block-iPACK group
Description: Group 1: Genicular nerve block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
Study NCT05156476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral triangle block-iPACK group
Description: Group 2: Femoral triangle block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
Study NCT05156476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration analgesia
Description: Group 3: LIA (performed by surgeon) Method: Blind injection Drug: a total of 200ml of 0.2% ropivacaine will be used (400mg). Of this, 150ml of ropivacaine 0.2% will be mixed with 1mg of adrenaline.
Study NCT05087849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nonavalent human papillomavirus vaccine
Description: Intralesional injection of nonavalent human papillomavirus vaccine (Gardasil 9) at 0 and 4 weeks
Study NCT04998682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Dissection
Description: A surgical procedure that opens the armpit (axilla) to identify, examine, or remove lymph nodes. Axillary dissection will be performed during SoC breast cancer surgery.
Study NCT05897970 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Return-to-sport (RTS) follow-up
Description: All sports patients who had a muscle evaluation at 3-4 months after ACLR since January 2017
Study NCT06693141 — intervention group
Intervention type: OTHER
Intervention: ESP block
Description: ESP block was applied to the patients.
Study NCT06693141 — intervention group
Intervention type: OTHER
Intervention: ITM
Description: ITM was applied to the patients.
Study NCT06687096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A recipe booklet
Description: A recipe resource with visuals in line with the low-residue diet recommendations given to patients before colonoscopy, including cooking instructions for the meals in the diet list.
Study NCT06687096 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standart diet list
Description: patients prepared with a routine colonoscopy preparation scheme
Study NCT05530291 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs
Study NCT06129123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live Free From E-cigarettes
Description: This is a 30-minute online educational program that focuses on providing information about e-cigarette and smoking social norms, harms of e-cigarettes and cigarettes, and ways to quit or reduce using e-cigarettes.
Study NCT06035211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3D model pré-operative education
Description: Before surgery, during a preoperative therapeutic education consultation, 3D models will be presented to the patients according to the allocated study group
Study NCT05545228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Link work intervention
Description: Intervention from a link worker to support participants to access dental services.
Study NCT05768087 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Escalated proton therapy
Description: According to allocated dose level: level 1-8, 69-90 Gy in 30 fractions of 2.3-3.0 Gy, to a subvolume of the radiation target
Study NCT06690866 — intervention group
Intervention type: BEHAVIORAL
Intervention: Stress
Description: Montreal Imaging Stress Task is a stress paradigm in the scanner to examine neuronal correlates of acute psychosocial stress.
Study NCT05307276 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Heliox
Description: Participants will then complete 1 FAM (#V3) to Neuromuscular Function Assessment (PRE-POST), Pre- and Post- Exercise Ventilatory Function Assessment, and a Constant Load Ergocycle Test to Tolerance Limit (intensity fixed at 90% of the maximum aerobic power, PMA). The following two experimental visits (#V4 and #V5) will replicate the tests described in #V3. However, during the constant load exercise, participants will breathe either ambient air or heliox (a mixture in which the nitrogen in the air is replaced by the inert gas helium) in a random order. During a final Experiential Visit (#V6), participants will replicate the Medical Gas Administration visit but the exercise will be interrupted when a similar amount of time/work as the ambient air condition is achieved.
Study NCT05307276 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Air
Description: Following the selection visit (#V0) to verify the inclusion and non-inclusion criteria, participants will make 2 visits (#V1 and #V2) including in particular a Respiratory Functional Exploration (EFR) and a triangular VO2 MAX estimation test in Ambient Air or Heliox conditions (depending on randomization).
Study NCT04976036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: 150 mg oral nintedanib soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
Study NCT05721755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT06175741 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: erector spinae plane block
Description: The ultrasound (US)-guided ESP block will be provided while the patient be in a seated position according to surgical site (right or left). Using high-frequency linear US transducer , the probe is placed in the longitudinal orientation lateral to thoracic third and six spinous processes ,then the trapezius muscle ,rhomboids major muscle and erector spinae muscle are identified and we will inject 20ml of 0.25% bupivacaine into interfacial plane below erector spinae muscle in one level (between T3and T6) ,alone in 1st group,with 3 mg morphine in 2nd group and 5 mg morphine in 3rd group
Study NCT06175741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: The ultrasound (US)-guided ESP block will be provided while the patient be in a seated position according to surgical site (right or left). Using high-frequency linear US transducer , the probe is placed in the longitudinal orientation lateral to thoracic third and six spinous processes ,then the trapezius muscle ,rhomboids major muscle and erector spinae muscle are identified and we will inject 20ml of 0.25% bupivacaine into interfacial plane below erector spinae muscle in one level (between T3and T6) ,alone in 1st group,with 3 mg morphine in 2nd group and 5 mg morphine in 3rd group
Study NCT06689124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized fentanyl
Description: After the enrollment process, the main research assistant will take a brown envelope containing the randomization and hand it to the principal investigator in numerical order. The principal investigator will then open the envelope to determine the group assignment for the patient, revealing which fentanyl nebulization dosage group (2 mcg/kg, 3 mcg/kg and 4 mcg/kg) the patient will be placed in. In this study, participants will be divided into three groups as previously described. We evaluate pain score at 0, 15, 30, 45, 60, 75, 90, 105 and 120 minutes after receiving nebulized fentanyl by a train research assistance who is blind from the treatment dosage.
Study NCT06688188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-JH12
Description: The dose will be 148-222 MBq given intravenously.
Study NCT06691477 — intervention group
Intervention type: OTHER
Intervention: No Interventions
Description: No intervention required. Subjects accepted regular medical treatment
Study NCT06689189 — intervention group
Intervention type: OTHER
Intervention: Blood fluorescence metabolite analysis
Description: This is an observational study and does not involve intervention. In both the early and late stages of sepsis, a significant increase in inflammatory free radicals changes the optical properties of the patient\&#39;s blood, distinguishing it from that of healthy individuals. To explore this phenomenon, 4 cc of fasting blood is drawn from patients who pass our screening criteria. This sample is then centrifuged in accordance with our detailed standard operating procedures to ready it for analysis. Subsequently, the fluorescence intensity of the blood is measured quantitatively using a precisely calibrated blood fluorometer, which is specifically designed to detect subtle variations indicative of both early and late sepsis. This entire process is executed under stringent quality control protocols to ensure the reliability and accuracy of the results, which are pivotal for the timely diagnosis and intervention in septic patients.
Study NCT06690476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose escalation(IPM514 monotherapy)
Description: Drug：IPM514 Intramuscular Injection A total of 7 administrations, including 2 cycles of vaccination with each cycle at QW × 3 doses; there is a 2-weeks interval between the two cycles, then followed by a boost dose 3 weeks after the 2'nd cycle.
Study NCT06690476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose expansion (IPM514 combined with tislelizumab)
Description: Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration The usage and dosage of the tislelizumab will be based on the drug instructions. IPM514 administration is planned to be concomitant with PD-1 antibody and to be stopped after 9 doses of treatment, while the PD-1 antibody will be continuously administered for a maximum of 1 year.
Study NCT06690476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)
Description: Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration Drug：cisplatin intravenous administration Drug：paclitaxel intravenous administration In this stage, subjects will receive the treatment of IPM514 combined with Tislelizumab, cisplatin and paclitaxel. All four drugs will be administered once every 3 weeks (± 1 day). IPM514 will be administered for the first time on D0, and Tislelizumab, cisplatin and paclitaxel will be administered for the first time on D3 (the administration order: Tislelizumab - paclitaxel - cisplatin). IPM514 will be administered a total of 3 times, and PD-1 antibody, cisplatin and paclitaxel will all be administered a total of 2 times (that is, IPM514 is administered on D0/D21/D42, and Tislelizumab, paclitaxel and cisplatin are administered on D3/D24).
Study NCT06687499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth-based susceptibility-guided treatment
Description: The investigators design four regimes for H. pylori eradication and participants receive one of the regimens based on susceptibility test. The four regimens are PBAT for those with both amoxicillin and tetracycline susceptible H. pylori; PBAM for those with amoxicillin susceptible but tetracycline resistant H. pylori; PBMT for those with amoxicillin resistant but tetracycline susceptible H. pylori; PBMR for those with both amoxicillin and tetracycline resistant H. pylori. A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e., esomeprazole (40 mg twice daily), R is rifabutin (150 mg twice daily), and T is tetracycline (500 mg thrice daily). The treatment duration is 14 days for all regimens.
Study NCT06691737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: Whole body vibration consists of 3-minute vibrations with a 30-second break. Participants were asked to step onto the platform barefoot and position their feet 3 from the center of the platform, with feet pointing forward, knees slightly bent, and upper limbs along the body. The training was divided into two parts: week 1 with a frequency of 20 Hz, and a constant amplitude of 3 mm.
Study NCT06690970 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga/18F-PSMA
Description: Each subject receive a single intravenous injection of 68Ga/18F-PSMA, and undergo PET/CT imaging within the specificed time.
Study NCT06687993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 2.5 mg
Description: 2.5 mg daily oral intake for 90 days
Study NCT06687993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg
Description: 5 mg daily oral intake for 90 days
Study NCT06687993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: daily oral intake for 90 days
Study NCT06687577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT-C
Description: Tobacco cessation treatment adapted for high risk population.
Study NCT06687577 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard behavioral tobacco cessation treatment.
Study NCT06634160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan
Description: Evaluation of the prevalence of steatosis by measuring ultrasound attenuation with Fibroscan® (non-invasive method, at a distance from a meal (3h fasting)).
Study NCT06634160 — intervention group
Intervention type: OTHER
Intervention: Sample collection
Description: 20 mL whole blood sample
Study NCT05721755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT05721755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT05721755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT05721755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT
Study NCT05721755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT
Study NCT05721755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT05721755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study NCT05721755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05721755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05721755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT05721755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT05721755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05721755 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study NCT05721755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05721755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05721755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05721755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05721755 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT06429683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexually transmitted diseases training for young adolescents aged 17-21
Description: Education
Study NCT05979090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mastery learning in communication skills
Description: Participants will undergo simulation-based mastery learning curriculum in difficult conversations.
Study NCT06211504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProStop, sinus tarsi implant (STI)
Description: Insertion of a sinus tarsi implant (ProStop from Arthrex) in sinus tarsi
Study NCT06211504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: MDCO - medial displacement calcaneal osteotomy FDL transfer - flexor digitorum longus tendon transfer to the navicular bone Spring ligament repair - reconstruction of the spring ligament Strayer's procedure - gastrocnemius recession (if necessary) Cotton osteotomy - medial cuneiform opening wedge osteotomy (if necessary)
Study NCT06211504 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgery
Description: MDCO - medial displacement calcaneal osteotomy FDL transfer - flexor digitorum longus tendon transfer to the navicular bone Spring ligament repair - reconstruction of the spring ligament Strayer's procedure - gastrocnemius recession (if necessary) Cotton osteotomy - medial cuneiform opening wedge osteotomy (if necessary)
Study NCT05635084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YN001
Description: Dose ranges from 2-90mg
Study NCT05635084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for YN001
Description: 5% dextrose injection to mimic the YN001
Study NCT06324487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Exercises
Description: Electrotherapy, stretching of the capsules, strengthening, ROM exercises, proprioceptive exercises
Study NCT06324487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Exercises
Description: Electrotherapy, stretching of the capsules, strengthening, ROM exercises, proprioceptive exercises
Study NCT06324487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy
Description: Strengthening exercises performed by using cuff surrounding proximal part of the arm.
Study NCT05848011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lorigerlimab
Description: Lorigerlimab is a DART® molecule that binds PD-1 and CTLA-4
Study NCT05848011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel Injection is a cytotoxic anticancer drug approved to treat prostate cancer
Study NCT05848011 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Description: Docetaxel Injection is a cytotoxic anticancer drug approved to treat prostate cancer
Study NCT05848011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: A corticosteroid drug approved for use with docetaxel in the treatment of prostate cancer
Study NCT05848011 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: A corticosteroid drug approved for use with docetaxel in the treatment of prostate cancer
Study NCT05674747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swift Microwave treatment - weekly x 4wks
Description: Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions).
Study NCT05674747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swift Microwave treatment - Every other week x 4wks
Description: Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions).
Study NCT05674747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swift Microwave treatment - Every other week x 24wks
Description: Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions).
Study NCT04935879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclacumab
Description: Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
Study NCT04935879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug